Blog
RSS FeedPosted by Michael Wonder on 29 Nov 2022
NICE’s new methods: putting innovation first, but at what cost?
28 November 2022 - Traditionally the gatekeeper to the NHS, NICE has increasingly reoriented its role towards facilitating access to innovative ...
Posted by Michael Wonder on 29 Nov 2022
Voclosporin with immunosuppressives for the treatment of patients with lupus nephritis
29 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 29 Nov 2022
Mepolizumab for the treatment of patients with severe hypereosinophilic syndrome
29 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 28 Nov 2022
Bayer’s Nubeqa receives MHRA approval to treat metastatic prostate cancer
28 November 2022 - The treatment will be made available immediately through an early access deal with NHS England. ...
Posted by Michael Wonder on 28 Nov 2022
NICE recommends Rinvoq (upadacitinib) as treatment option for moderately to severely active ulcerative colitis in adults
25 November 2022 - Publication of positive Final Draft Guidance from NICE is supported by data from three clinical studies that ...
Posted by Michael Wonder on 24 Nov 2022
New life-extending treatment for rare forms of advanced gastro-oesophageal cancer recommended by NICE
24 November 2022 - Around 3,000 people could be eligible for a new life-extending combination therapy to treat rare forms of ...
Posted by Michael Wonder on 24 Nov 2022
Luspatercept for the treatment of patients with anaemia caused by myelodysplastic syndrome
24 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 24 Nov 2022
Luspatercept for the treatment of patients with anaemia caused by beta thalassaemia
24 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 23 Nov 2022
Axicabtagene ciloleucel for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after one systemic treatment
23 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 22 Nov 2022
NICE recommends Sobi’s Doptelet to treat thrombocytopenia
18 November 2022 - Primary ITP is a rare autoimmune condition characterised by high platelet destruction ...
Posted by Michael Wonder on 22 Nov 2022
Carfilzomib in combination with daratumumab and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma
22 November 2022 - NICE is unable to make a recommendation on the use of carfilzomib in combination with daratumumab and ...
Posted by Michael Wonder on 22 Nov 2022
Tisagenlecleucel for the treatment of patients with follicular lymphoma after two or more therapies
22 November 2022 - NICE is unable to make a recommendation on the use of tisagenlecleucel for the treatment of adults ...
Posted by Michael Wonder on 17 Nov 2022
NICE recommends 3 treatments for COVID-19 in draft guidance
16 November 2022 - Three treatments for COVID have been recommended in draft NICE guidance released today for public consultation. ...
Posted by Michael Wonder on 17 Nov 2022
A tussle over medicines pricing is looming in Britain
15 November 2022 - Agreement to limit the size of the NHS drugs bill under strain. ...
Posted by Michael Wonder on 17 Nov 2022
Ruxolitinib phosphate for the treatment of patients with chronic graft versus host disease that is refractory to the use of corticosteroids
16 November 2022 - NICE is unable to make a recommendation about the use in the NHS of ruxolitinib phosphate for ...